ColoSTAT Economic Study - Australian Public Health Savings

• ColoSTAT blood test could save $72 million annually for public hospitals
• Estimated 29,400 fewer colonoscopies needed per year
• Study to support Medicare reimbursement application

Rhythm Biosciences Ltd has announced the results of an independent health economic study on ColoSTAT, its blood test for bowel cancer. The study, conducted by Value-Based Access Pty Ltd, suggests that using ColoSTAT could save public hospitals around $72 million annually by reducing unnecessary colonoscopies. The study estimates a 36% reduction in colonoscopies, saving approximately $4.50 for every $1 spent on the test. The study focused on public hospitals, with plans to assess potential benefits in private hospitals. The findings will support Rhythm's application to the Medical Services Advisory Committee (MSAC) for Medicare reimbursement, a key milestone for commercial success.